| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide Cardiovascular disease, Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Completed | 833 | Jun 2023 | 19 | results |
| REDEFINE 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema / cagrilintide, Semaglutide Cardiovascular disease, Obesity / overweight | HbA1c 6.5-10% | Ph 3 | Active, not recruiting | 631 | Sep 2027 | — | |
| ESSENCEResearch Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | — | Ph 3 | Active, not recruiting | 556 | Apr 2029 | 3 | |
| EVOKE PlusA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide Alzheimer's / cognition | — | Ph 3 | Completed | 495 | Sep 2025 | 4 | |
| SOULA Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide Cardiovascular disease, Chronic kidney disease, Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 492 | Aug 2024 | 6 | results |
| EVOKEA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Semaglutide Alzheimer's / cognition | — | Ph 3 | Completed | 444 | Sep 2025 | 3 | |
| NCT04469855Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic® | Semaglutide Type 2 diabetes | — | — | Completed | 414 | May 2025 | — | |
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide Chronic kidney disease, Type 2 diabetes | HbA1c ≤10% | Ph 3 | Completed | 413 | Jan 2024 | 13 | results |
| REIMAGINE 2A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 405 | Nov 2025 | — | |
| NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥35 | Ph 3 | Recruiting | 303 | Feb 2028 | — | |
| COMBINE 1A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Semaglutide Type 2 diabetes | — | Ph 3 | Completed | 281 | Mar 2024 | 1 | results |
| NCT05016882Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | CagriSema / cagrilintide, NNC0194-0499, Semaglutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 255 | Dec 2024 | — | |
| REDEFINE 1A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 254 | Oct 2024 | 2 | |
| SUSTAIN™ 6Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 253 | Mar 2016 | 21 | results |
| PIONEER 3Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 242 | Feb 2017 | 9 | results |
| WAYFINDStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | BMI ≥23 | Ph 2 | Completed | 242 | Nov 2024 | — | results |
| NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 239 | Mar 2025 | — | results |
| SUSTAIN™ 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 231 | Sep 2015 | 12 | results |
| FOCUSA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Active, not recruiting | 229 | Nov 2027 | — | |
| PIONEER 6A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 228 | Sep 2018 | 14 | results |
| PIONEER PLUSResearch Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 228 | Mar 2023 | 1 | results |
| SUSTAIN 11A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c ≥7.5% | Ph 3 | Completed | 210 | Feb 2021 | 1 | results |
| SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Dulaglutide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 209 | Apr 2017 | 13 | results |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 196 | Mar 2026 | — | |
| STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 194 | Jun 2024 | 1 | results |
| NCT05013229A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) | Semaglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 182 | Nov 2023 | 1 | |
| STEP HFpEF DMResearch Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Semaglutide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 180 | Oct 2023 | 13 | |
| REDEFINE 2A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 179 | Jan 2025 | 1 | |
| NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Efinopegdutide, Semaglutide MASH / NAFLD / liver fibrosis | HbA1c ≤9% | Ph 2 | Completed | 175 | Dec 2025 | — | |
| REIMAGINE 5A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Active, not recruiting | 163 | Jun 2026 | — | |
| NCT02970942Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 2 | Completed | 158 | Feb 2020 | 7 | results |
| NCT02461589Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 150 | Oct 2016 | 1 | results |
| NCT06717698A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | NNC0519-0130, Semaglutide Chronic kidney disease, Obesity / overweight | — | Ph 2 | Recruiting | 147 | Sep 2026 | — | |
| STEP 2Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 147 | Mar 2020 | 6 | results |
| SUSTAIN™ 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Exenatide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 146 | Jul 2015 | 18 | results |
| STEP-HFpEFResearch Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Semaglutide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 146 | Apr 2023 | 7 | results |
| SUSTAIN™ 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 141 | Oct 2015 | 18 | results |
| COMBINE 2A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 136 | Dec 2023 | 1 | results |
| ACHIEVE-3A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron, Semaglutide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 131 | Aug 2025 | 1 | |
| NCT05486065A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 130 | Oct 2023 | — | results |
| SUSTAIN FORTEA Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 8-10% | Ph 3 | Completed | 129 | Sep 2020 | 1 | results |
| NCT05144984A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes | NNC0480-0389, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 129 | Feb 2023 | — | results |
| STEP 1STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 128 | Mar 2020 | 11 | results |
| NCT06131372A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | CagriSema / cagrilintide, Semaglutide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 128 | Sep 2025 | — | |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| NCT03596450Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial | Semaglutide Type 2 diabetes | — | Ph 4 | Completed | 122 | Jun 2022 | 2 | results |
| NCT05064735Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Semaglutide Obesity / overweight, Osteoarthritis | BMI ≥30 | Ph 3 | Completed | 122 | Jul 2023 | 1 | results |
| AMAZE 8AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Amycretin / zenagamtide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Not yet recruiting | 120 | Dec 2028 | — | |
| NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Recruiting | 119 | Mar 2030 | — | |
| SUSTAIN 8Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 119 | Oct 2018 | 5 | results |
| PIONEER 8Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 118 | Jan 2018 | 5 | results |
| COMBINE 4A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | Semaglutide Type 2 diabetes | HbA1c ≥8% | Ph 3 | Completed | 118 | May 2025 | — | |
| PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Semaglutide Renal impairment, Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 117 | Apr 2018 | 7 | results |
| NCT07357766A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Not yet recruiting | 116 | Nov 2027 | — | |
| NCT06283667Special Use - Results Surveillance on Long-term Use With Wegovy® | Semaglutide Obesity / overweight | BMI ≥27 | — | Active, not recruiting | 112 | Jan 2028 | — | |
| PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 108 | Aug 2017 | 7 | results |
| STEP UPA Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 107 | Oct 2024 | 1 | results |
| PIONEER 2Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 106 | Aug 2017 | 8 | results |
| PIONEER 1Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 105 | Oct 2017 | 10 | results |
| NCT05478252A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 104 | Aug 2023 | — | results |
| NCT01923181Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes | Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-9.5% | Ph 2 | Completed | 103 | Dec 2014 | 1 | results |
| NCT06409130Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | CagriSema / cagrilintide, NNC0194-0499, Semaglutide Alcohol / substance use, MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 102 | Nov 2025 | — | |
| NCT06083675Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Withdrawn | 100 | Jan 2025 | — | |
| SUSTAIN™ 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 99 | Nov 2015 | 11 | results |
| PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 97 | Apr 2025 | — | |
| SOLSTICEEfficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. | AZD5004 / ECC5004, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 97 | Dec 2025 | — | |
| SURE GERMANYA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 95 | May 2021 | 1 | |
| NCT06571383STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Semaglutide Obesity / overweight | Age 12-15 | Ph 4 | Active, not recruiting | 93 | Nov 2028 | — | |
| PIONEER 12A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 93 | Oct 2021 | 1 | results |
| SUSTAIN 10Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 92 | Jul 2018 | 2 | results |
| NCT05579977Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | GLP-1 / incretin class catch-all, Lotiglipron, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 2 | Terminated | 90 | Jul 2023 | 2 | results |
| SUSTAIN™1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 86 | May 2015 | 13 | results |
| PIONEER 7Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Semaglutide Type 2 diabetes | HbA1c 7.5-9.5% | Ph 3 | Completed | 83 | Feb 2018 | 7 | results |
| NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | Cotadutide, Semaglutide Chronic kidney disease, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 83 | Mar 2022 | 3 | results |
| NCT04153929A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. | Semaglutide, Survodutide Obesity / overweight, Type 2 diabetes | BMI 25-50 | Ph 2 | Completed | 80 | Oct 2021 | 1 | results |
| NCT06260722Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Retatrutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 77 | Aug 2026 | — | |
| NCT00696657A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 77 | Feb 2009 | 1 | results |
| NCT05649137A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 76 | Oct 2024 | 1 | results |
| NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Liraglutide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 74 | Mar 2017 | 2 | results |
| SUSTAIN 9Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 72 | Jul 2018 | 1 | results |
| STEP 4Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 72 | Feb 2020 | 6 | results |
| NCT04944992A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Efinopegdutide, Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 69 | Oct 2022 | 1 | results |
| SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 67 | Mar 2019 | 2 | results |
| NCT06738979A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Semaglutide Obesity / overweight | BMI ≥28 | Ph 3 | Not yet recruiting | 66 | Jul 2026 | — | |
| PIONEER 11A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 66 | Sep 2021 | 1 | results |
| NCT07415954A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Recruiting | 63 | Sep 2027 | — | |
| NCT07357740A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-39.9 | Ph 2 | Not yet recruiting | 61 | Aug 2027 | — | |
| COURAGEA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Semaglutide Healthy volunteers, Obesity / overweight | BMI 18-32 | Ph 2 | Active, not recruiting | 60 | May 2026 | — | |
| NCT06897475A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Recruiting | 60 | Dec 2026 | — | |
| STEP YoungA Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Semaglutide Obesity / overweight | HbA1c ≤10% | Ph 3 | Active, not recruiting | 56 | Oct 2025 | — | |
| REIMAGINEYOUNGA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Not yet recruiting | 56 | Sep 2029 | — | |
| OASIS 1Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 56 | Mar 2023 | 1 | results |
| NCT06797869A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | CagriSema / cagrilintide, Semaglutide Diabetic neuropathy, Type 2 diabetes | BMI ≥25 | Ph 2 | Active, not recruiting | 54 | Aug 2026 | — | |
| SURE FRANCEA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 53 | Sep 2021 | 1 | |
| REIMAGINE 3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 53 | Sep 2025 | — | |
| NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide Obesity / overweight | HbA1c ≤10% | Ph 3 | Completed | 51 | Mar 2022 | 4 | results |
| NCT07112872A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | CT-996 / RO7795081, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Active, not recruiting | 50 | Nov 2026 | — | |
| REIMAGINE 1A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | CagriSema / cagrilintide, Semaglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 50 | Oct 2025 | — | |
| REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Semaglutide Chronic kidney disease, Type 2 diabetes | eGFR ≥30 | Ph 3 | Completed | 49 | Nov 2024 | 3 | results |
| NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 46 | Mar 2027 | — | |
| NCT06131437A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 46 | Dec 2025 | — | |
| SUSTAIN™A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 43 | Feb 2016 | 4 | results |
| STEP 10Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Semaglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 3 | Completed | 43 | Jan 2023 | 1 | results |
| STEP 3Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 41 | Mar 2020 | 6 | results |
| STEP 5Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 41 | Jan 2021 | 5 | results |
| SURE ITALYA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 39 | Jul 2021 | 1 | |
| NCT05813912A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Completed | 39 | Apr 2025 | — | |
| NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 38 | Apr 2021 | 1 | results |
| SELECT-LIFESELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial | Semaglutide Cardiovascular disease, Obesity / overweight | — | — | Completed | 38 | Aug 2025 | — | |
| REDEFINE 6A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 37 | Jan 2025 | — | |
| PRECIDENTDPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Cardiovascular disease, Type 2 diabetes | Established ASCVD/CKD | Ph 4 | Recruiting | 36 | Mar 2029 | 1 | |
| NCT06780449A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 36 | Aug 2028 | — | |
| NCT05816057A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus | Semaglutide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 35 | Jul 2023 | — | |
| PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Dulaglutide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 34 | Jul 2018 | 5 | results |
| STEP7Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Semaglutide Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 33 | Aug 2022 | 1 | results |
| NCT07284979Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | HRS9531, Semaglutide Obesity / overweight | BMI ≥35 | Ph 3 | Recruiting | 32 | Mar 2028 | — | |
| SURMOUNT-5A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 32 | Nov 2024 | 3 | results |
| SURE UKA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 31 | Aug 2020 | 2 | |
| PILLARA Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice | Semaglutide Obesity / overweight | — | — | By invitation | 30 | Aug 2028 | — | |
| NCT03648281A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 30 | Jan 2020 | 2 | |
| NCT03631186A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 28 | Dec 2019 | 2 | |
| STEP 6STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Semaglutide Obesity / overweight | HbA1c 7-10% | Ph 3 | Completed | 28 | Nov 2020 | 3 | results |
| NCT05813925A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 28 | Jan 2025 | 1 | |
| SURE NLA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 27 | Nov 2020 | 1 | |
| COMBAT_T2_NASHCombined Active Treatment in Type 2 Diabetes with NASH | Semaglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | HbA1c ≤9.5% | Ph 4 | Active, not recruiting | 26 | Jan 2025 | — | |
| NCT05616013Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 26 | May 2024 | 2 | results |
| SUSTAIN™A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 6.5-9.5% | Ph 3 | Completed | 25 | Nov 2015 | 2 | results |
| SUSTAIN SWITCHSUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Withdrawn | 25 | Nov 2020 | — | |
| NCT04969939A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity | NNC0165-1875, Semaglutide Obesity / overweight | BMI 30-45 | Ph 2 | Completed | 25 | Dec 2022 | — | results |
| REALYSEA Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) | Semaglutide Type 2 diabetes | HbA1c ≥7% | Ph 4 | Completed | 25 | Jun 2025 | — | |
| DOORSDOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy | Semaglutide Type 2 diabetes | HbA1c ≥7.5% | — | Completed | 25 | Oct 2024 | — | |
| NCT06388187A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 3 | Completed | 25 | Apr 2026 | — | |
| NCT07639021A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Semaglutide Obesity / overweight | — | Ph 2 | Not yet recruiting | 25 | Jul 2027 | — | |
| NCT04982575Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes | CagriSema / cagrilintide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 23 | Jul 2022 | 1 | results |
| OASIS 4Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Semaglutide Obesity / overweight | — | Ph 3 | Completed | 23 | Apr 2024 | 1 | results |
| FLAMESFibrosis Lessens After Metabolic Surgery | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery Candidate, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 22 | May 2029 | — | |
| STEP12A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Semaglutide Obesity / overweight | BMI ≥24 | Ph 3 | Completed | 21 | Apr 2025 | — | results |
| O-SEMA-FastO-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait | Semaglutide Type 2 diabetes | — | — | Completed | 20 | Jul 2023 | 1 | |
| STEP 8Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Liraglutide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 19 | Mar 2021 | 3 | results |
| NCT03987074Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | Semaglutide MASH / NAFLD / liver fibrosis | BMI ≥23 | Ph 2 | Completed | 18 | Jul 2020 | 2 | results |
| MIRAGEA Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE) | Semaglutide Type 2 diabetes | — | — | Completed | 17 | Jul 2022 | — | |
| CBeyondStudy to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Semaglutide Obesity / overweight | HbA1c ≤6.5% | Ph 2 | Active, not recruiting | 16 | Nov 2026 | — | |
| PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 6.5-9.5% | Ph 3 | Completed | 16 | Jan 2018 | 4 | results |
| SURE SPAINA Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 16 | Jul 2021 | — | |
| NCT04998136Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Semaglutide Obesity / overweight | BMI ≥25 | Ph 3 | Completed | 16 | Oct 2023 | 1 | results |
| OASIS 3Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Semaglutide Obesity / overweight | HbA1c 7-10% | Ph 3 | Completed | 16 | Jan 2025 | — | |
| NCT07502508Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Semaglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Recruiting | 16 | Jun 2027 | — | |
| NCT07271251A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Active, not recruiting | 15 | Jun 2026 | — | |
| NCT07505303MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 15 | Nov 2026 | — | |
| NCT06633783A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® | Semaglutide Obesity / overweight | BMI ≥28 | Ph 3 | Not yet recruiting | 14 | May 2026 | — | |
| NCT03724981A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | Dulaglutide, Semaglutide Type 2 diabetes | — | Ph 4 | Completed | 14 | Apr 2019 | 1 | results |
| SEMASEARCHSEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY® | Semaglutide Obesity / overweight | BMI ≥40 · Established CVD | — | Completed | 14 | Jun 2025 | 1 | |
| QUALITYDose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 14 | Apr 2025 | — | |
| NCT06771115Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Semaglutide Obesity / overweight | BMI 30-42 | Ph 2 | Completed | 14 | Sep 2025 | — | |
| SERENASemaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | GLP-1 / incretin class catch-all, Semaglutide Gestational diabetes, Prediabetes / glucose intolerance | Female | Ph 3 | Recruiting | 13 | Jun 2029 | — | |
| SMARTSeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes | Semaglutide Chronic kidney disease, Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 13 | May 2024 | 1 | |
| OASIS 2Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Semaglutide Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 13 | Jul 2023 | 1 | |
| NCT07466017A Study of CS060380 Tablets in Patients With MASH and Obesity | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 12 | Apr 2027 | 3 | |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Semaglutide Alzheimer's / cognition | — | Ph 3 | Completed | 11 | Aug 2024 | — | results |
| NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Semaglutide Healthy volunteers, Obesity / overweight | BMI 25-40 | Ph 3 | Recruiting | 10 | Dec 2026 | — | |
| PLATEAUProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Semaglutide Obesity / overweight | BMI ≥35 | Ph 2 | Recruiting | 10 | Oct 2027 | — | |
| SEMPATICOSemaglutide to Reduce Myocardial Injury in PATIents With COVID-19 | Semaglutide COVID / long COVID | BMI ≥30 | Ph 2 | Unknown | 10 | Mar 2022 | — | |
| RESOLVE-2Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Semaglutide Obesity / overweight | BMI 30-45 | Ph 2 | Active, not recruiting | 9 | Aug 2026 | — | |
| NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide HIV, MASH / NAFLD / liver fibrosis, Obesity / overweight, Prediabetes / glucose intolerance | HbA1c 5.7-6.5% | Ph 2 | Completed | 9 | Mar 2023 | 4 | results |
| NCT07018544A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea | Semaglutide Obesity / overweight | — | — | By invitation | 8 | Feb 2027 | — | |
| NCT06751589A Study of a Weight Loss Intervention in People With Endometrial Cancer | Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Early Ph 1 | Recruiting | 7 | Dec 2027 | — | |
| PROACTA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Sarcopenia / muscle | BMI ≥30 | Ph 2 | Recruiting | 7 | Mar 2027 | — | |
| NCT07302802Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice | Semaglutide Hypothalamic / syndromic obesity, Obesity / overweight | — | — | Recruiting | 7 | Jun 2028 | 5 | |
| DehydraTECHComparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Semaglutide, Tirzepatide Obesity / overweight | BMI 0-40 | Ph 1 | Completed | 7 | Jul 2025 | — | |
| NCT07628985BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | GZR18, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Not yet recruiting | 7 | Oct 2027 | 2 | |
| NCT02016911Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment | Semaglutide Healthy volunteers, Hepatic impairment | BMI 18.5-40 | Ph 1 | Completed | 6 | Jan 2015 | 2 | |
| NCT06478550A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment | Semaglutide Type 2 diabetes | — | — | Completed | 6 | Apr 2025 | — | |
| NCT07622810BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | GZR18, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Not yet recruiting | 6 | Dec 2027 | — | |
| NCT06042153DIALYSIS-TIR Study | Semaglutide Chronic kidney disease, Type 2 diabetes | — | Ph 4 | Active, not recruiting | 5 | Sep 2027 | — | |
| SEQEffect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. | Semaglutide Obesity / overweight, Reproductive / infertility | BMI 27-40 | Ph 4 | Recruiting | 5 | Feb 2027 | 19 | |
| SHIFTSemaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Semaglutide Alcohol / substance use | — | Ph 2 | Not yet recruiting | 5 | Jan 2027 | — | |
| LIFETRAINPersonalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) | Semaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥27 | Not applicable | Not yet recruiting | 5 | Jul 2030 | — | |
| BESTMEDBESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | — | Unknown | 5 | Jun 2024 | 3 | |
| RT1DTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | Semaglutide Chronic kidney disease, Type 1 diabetes | eGFR ≥20 | Ph 2 | Recruiting | 4 | Jun 2027 | 1 | |
| NCT07064486A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | BGM0504, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 3 | Recruiting | 4 | Jul 2026 | — | |
| GLP1-TASTEChanges in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | — | — | Recruiting | 4 | Jan 2027 | 1 | |
| CKD-bioMatchA Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | Semaglutide Chronic kidney disease | UACR 100-5000 | Ph 4 | Recruiting | 4 | Jun 2028 | — | |
| NCT02014259Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function | Semaglutide Healthy volunteers, Renal impairment | BMI 18.5-40 | Ph 1 | Completed | 4 | Oct 2014 | 1 | |
| NCT02210871Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Semaglutide Healthy volunteers, Hepatic impairment | BMI 18.5-40 | Ph 1 | Completed | 4 | Jun 2015 | 1 | |
| NCT04032197A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes | Semaglutide Cardiovascular disease, Type 2 diabetes | BMI ≤39.9 · Established CVD | Ph 1 | Completed | 4 | Dec 2022 | 1 | |
| ADJUST-T1DADJUnct Semaglutide Treatment in Type 1 Diabetes | Semaglutide Obesity / overweight, Type 1 diabetes | BMI ≥30 | Ph 2 | Completed | 4 | Aug 2024 | 1 | results |
| NCT06400615Study That Tests AD109 in Patients Taking GLP-1 Drugs | Liraglutide, Semaglutide, Tirzepatide Obesity / overweight, Sleep apnea | BMI 27-43 | Ph 2 | Completed | 4 | Dec 2024 | — | |
| NCT04892199Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Prediabetes / glucose intolerance, Psychiatric (schizophrenia / bipolar / depression), Type 2 diabetes | BMI ≥25 | Ph 4 | Active, not recruiting | 3 | Mar 2026 | 2 | |
| NCT05872022A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy | Semaglutide Obesity / overweight | Female | — | By invitation | 3 | Oct 2032 | — | |
| NCT06431308Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 3 | Feb 2026 | — | |
| SEMAHEARTMechanisms of Semaglutide Therapy in Heart Failure Patients | Semaglutide Heart failure, Obesity / overweight | — | Ph 1/2 | Recruiting | 3 | Jul 2025 | — | |
| EPHIC-DIA2Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Dulaglutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Active, not recruiting | 3 | Jun 2026 | — | |
| GLICHGLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | GLP-1 / incretin class catch-all, Semaglutide Stroke | — | Ph 2 | Not yet recruiting | 3 | Jun 2028 | — | |
| NCT00833716Effect of Renal Impairment on the Pharmacokinetics of NN9535 | Semaglutide Healthy volunteers, Renal impairment | BMI ≤40 | Ph 1 | Completed | 3 | Jul 2010 | 2 | |
| NCT05227196A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People | Semaglutide Healthy volunteers | BMI 21-32 | Ph 1 | Completed | 3 | Jun 2023 | 1 | |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 3 | Apr 2023 | — | |
| NCT05533632Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 4 | Completed | 3 | Jan 2024 | — | results |
| NCT06548490GLP-1R Agonist Treatment for Opioid Use Disorder | Semaglutide Alcohol / substance use | BMI ≥18 | Ph 2 | Recruiting | 3 | Nov 2026 | 2 | |
| NCT06804603A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | Semaglutide Healthy volunteers, Obesity / overweight | BMI 25-40 | Ph 2 | Completed | 3 | Oct 2025 | — | |
| NCT05784402A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants | Semaglutide Healthy volunteers | BMI 23-34.9 | Ph 1 | Completed | 3 | Feb 2024 | — | |
| NCT04019197Effects of Semaglutide in HIV-Associated Lipohypertrophy | Semaglutide HIV, Obesity / overweight | BMI ≥25 | Ph 2 | Active, not recruiting | 2 | Apr 2024 | 3 | results |
| NCT05173714Sit Less, Interact and Move More (SLIMM) 2 Study | Semaglutide Chronic kidney disease | eGFR 20-60 | Ph 2 | Recruiting | 2 | Dec 2026 | — | |
| NCT05756764Anti-obesity Pharmacotherapy and Inflammation | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 2 | Jan 2026 | — | |
| T1-DISCOType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | Semaglutide Type 1 diabetes | BMI 20-45 | Ph 3 | Recruiting | 2 | Oct 2027 | — | |
| NCT05925959Preoperative Weight Loss for Open Abdominal Wall Reconstruction | Liraglutide, Semaglutide Obesity / overweight | BMI 40-55 | Not applicable | Recruiting | 2 | Jun 2027 | 1 | |
| Steno1Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes | Semaglutide Type 1 diabetes | BMI ≥35 | Ph 3 | Recruiting | 2 | Jul 2029 | 1 | |
| NCT06173778Semaglutide for Post-Smoking Cessation Weight Management | Semaglutide Alcohol / substance use, Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 2 | Jul 2026 | 1 | |
| ObGeSemaReal-life Evaluation of WEGOVY (Semaglutide) Treatment in Adults With Monogenic Obesity (ObGeSema) | Semaglutide Hypothalamic / syndromic obesity, Obesity / overweight | — | — | Recruiting | 2 | Apr 2027 | — | |
| NCT06497595Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Not applicable | Not yet recruiting | 2 | Jan 2025 | — | |
| SEMINAL-AFSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation | Semaglutide Atrial fibrillation, Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 2 | Dec 2027 | — | |
| STACEvaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Semaglutide Alcohol / substance use, HIV | BMI 20-50 | Ph 2 | Recruiting | 2 | Jul 2026 | — | |
| NCT06706284Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Semaglutide Spinal Cord Injuries, Type 2 diabetes | BMI ≥22 | Ph 4 | Recruiting | 2 | Sep 2028 | — | |
| MAINTAINMAINTAIN (Mucosal AblatIoN Therapy After INcretins) | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 2 | Jun 2026 | 3 | |
| NCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Semaglutide, Survodutide Obesity / overweight | BMI 30-45 | Ph 1 | Active, not recruiting | 2 | Jan 2027 | — | |
| NCT06814938A Study of a Novel Precision Medicine Approach For Obesity | Semaglutide Obesity / overweight | BMI ≥30 | Ph 4 | Recruiting | 2 | Dec 2027 | — | |
| NCT06836284The Evira Study: Additional Support During Obesity Treatment | Liraglutide, Semaglutide Obesity / overweight | Age 12-17 | Not applicable | Recruiting | 2 | Apr 2027 | — | |
| SPOT-DMSemaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Semaglutide | BMI ≥25 | Ph 2/3 | Not yet recruiting | 2 | Nov 2027 | — | |
| NCT07184086A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | CagriSema / cagrilintide, Semaglutide Obesity / overweight | — | Ph 1 | Recruiting | 2 | Oct 2027 | — | |
| NCT07285902A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | HRS9531, Semaglutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 2 | Mar 2027 | — | |
| STABLE-GLP1GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | Semaglutide Type 2 diabetes | EF ≥50% | Ph 4 | Recruiting | 2 | Mar 2027 | 1 | |
| NCT07444073Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥27.5 | — | Not yet recruiting | 2 | Dec 2026 | 1 | |
| SEMA-REAL ARGStudy of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin | Semaglutide Type 2 diabetes | HbA1c 7-12% | — | Recruiting | 2 | Dec 2027 | 7 | |
| BAT-SemaBrown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study) | Semaglutide Obesity / overweight | BMI ≥27 · Established CVD | Not applicable | Not yet recruiting | 2 | Feb 2028 | — | |
| NCT02877355Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. | Semaglutide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Type 2 diabetes | BMI 18.5-39.9 | Ph 1 | Completed | 2 | Nov 2017 | 1 | |
| NCT03357380A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 25-40 | Ph 1 | Completed | 2 | Mar 2020 | 2 | |
| NCT03574584A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese | Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 2 | Jul 2019 | — | |
| NCT03951753A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 1 | Completed | 2 | Apr 2021 | 2 | results |
| NCT04012255A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity | Semaglutide Obesity / overweight | BMI 27-34.9 | Ph 1 | Terminated | 2 | Aug 2019 | — | |
| NCT04126603Impact of Semaglutide on CD34+ EPC and Fat Derived MSC | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 2 | Oct 2023 | — | results |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | May 2023 | 1 | |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | Sep 2022 | 1 | |
| RAISE-KTEffect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 3 | Terminated | 2 | Jan 2023 | — | results |
| NCT04940078A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 2 | Jan 2022 | — | |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | Mar 2023 | — | |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | Oct 2023 | 2 | |
| NCT05316662A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | Apr 2024 | — | |
| PIONEER REALA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice | Semaglutide Type 2 diabetes | — | — | Completed | 2 | Jul 2024 | 1 | |
| RESETTLEYoung Adults With Early-onset Obesity Treated With Semaglutide | Semaglutide Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 2 | Apr 2026 | 23 | |
| SEMA-VRSemaglutide and Vascular Regeneration | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 4 | Unknown | 2 | Dec 2024 | 11 | |
| GALLOPGlucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies | GLP-1 / incretin class catch-all, Semaglutide Stroke | — | Ph 2 | Completed | 2 | Oct 2024 | 1 | |
| IIH:DUALThe Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure | Semaglutide Obesity / overweight, Pseudotumor Cerebri | BMI ≥27 | Ph 4 | Completed | 2 | Jan 2025 | — | |
| NCT06533527Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Dulaglutide, Liraglutide, Semaglutide, Tirzepatide Perioperative / gastric aspiration risk | — | Ph 4 | Completed | 2 | May 2025 | 4 | results |
| NCT06820047Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study | GLP-1 / incretin class catch-all, Semaglutide Bariatric Surgery, Bariatric Surgery Candidate, Obesity / overweight | BMI ≥35 | — | Completed | 2 | Jul 2023 | 1 | |
| NCT07297238Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. | GLP-1 / incretin class catch-all, Semaglutide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Not applicable | Recruiting | 2 | May 2026 | 14 | |
| NCT03598621A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools | Semaglutide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 2 | Jan 2019 | — | |
| NCT04817644A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets | Semaglutide Healthy volunteers | BMI 20-32.4 | Ph 1 | Completed | 2 | May 2023 | — | |
| NCT05129891A Research Study Looking at New Protein-based Tablets in Healthy Male Participants | Semaglutide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 2 | Feb 2023 | — | |
| NCT05249881"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan." | Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Early Ph 1 | Unknown | 2 | Dec 2022 | — | |
| NCT05429593A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet | Semaglutide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 2 | Mar 2023 | — | |
| NCT07627074Weight Loss in Adults Using Semaglutide (Real-world Study) | Semaglutide Obesity / overweight | BMI ≥27 | — | Recruiting | 2 | Jun 2026 | — | |
| NCT01511393An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | Dulaglutide, Exenatide, Liraglutide, Semaglutide Oncology | — | — | By invitation | 1 | Dec 2039 | 1 | |
| NCT03884075Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) | Semaglutide Healthy volunteers, MASH / NAFLD / liver fibrosis | Healthy volunteers | Ph 2 | Recruiting | 1 | Aug 2026 | — | |
| NCT03899402Triple Therapy in T1DM | Semaglutide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 2/3 | Active, not recruiting | 1 | Jan 2026 | — | |
| SWIFTSemaglutide's Efficacy in Achieving Weight Loss for Those With HIV | Semaglutide HIV, Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Jan 2027 | 1 | |
| SWEETTreatment to Regress to Normoglycemia in Women with a Recent History of GDM | Semaglutide Gestational diabetes, Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥25 | Ph 4 | Recruiting | 1 | Jan 2026 | — | |
| QUESTLifestyle Counseling and Medication for Adolescent Weight Management | Semaglutide Obesity / overweight | Age 12-17 | Ph 2 | Active, not recruiting | 1 | Jun 2026 | — | |
| NCT04990024The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide | Semaglutide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Sep 2025 | — | |
| CHANGEChanging the Natural History of Type 2 Diabetes ("CHANGE" Study) | Semaglutide Type 2 diabetes | HbA1c 6-7.4% | Not applicable | Active, not recruiting | 1 | Jan 2027 | 1 | |
| NCT05067621Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥85 | Ph 2 | Active, not recruiting | 1 | Dec 2026 | — | |
| PORTPharmacogenetics of Response to GLP1R Agonists | Semaglutide Obesity / overweight | BMI ≥27 | Ph 1 | Recruiting | 1 | Nov 2026 | 1 | |
| BARI-STEPSemaglutide 2.4 mg in Patients With Poor Weight-loss | Semaglutide Bariatric Surgery, Obesity / overweight | — | Ph 3 | Active, not recruiting | 1 | Mar 2025 | 1 | |
| NCT05195944Semaglutide vs Sitagliptin | Semaglutide Diabetes (other / unspecified), Liver Transplant; Complications, Type 2 diabetes | HbA1c 6.5-10.5% | Ph 4 | By invitation | 1 | Dec 2026 | — | |
| NCT05202353A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | Semaglutide, Survodutide Obesity / overweight | BMI 30-40 | Ph 1 | Recruiting | 1 | Dec 2026 | — | |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| GATA-3Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Sep 2026 | 1 | |
| SemaSemaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity | Semaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥30 | Not applicable | Active, not recruiting | 1 | Aug 2026 | — | |
| GAROSGenetics of the Acute Response to Oral Semaglutide | Semaglutide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Dec 2025 | — | |
| NCT05371496Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction | Semaglutide Heart failure, Obesity / overweight | BMI ≥30 | Ph 2 | By invitation | 1 | Aug 2026 | — | |
| NCT05419726Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects. | Semaglutide Obesity / overweight | — | — | Recruiting | 1 | Jan 2026 | 20 | |
| NCT05424003Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant | Semaglutide Diabetes (other / unspecified), Liver Transplant; Complications, Obesity / overweight, Prediabetes / glucose intolerance | HbA1c ≥6.5% | Ph 2 | Recruiting | 1 | Feb 2026 | — | |
| ASCEND PLUSA Study of Cardiovascular Events iN Diabetes Plus | Semaglutide Type 2 diabetes | — | Ph 4 | Recruiting | 1 | Aug 2028 | — | |
| NCT05503927A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy | Semaglutide Obesity / overweight | BMI ≥30 | — | By invitation | 1 | Aug 2027 | — | |
| StoryLCSSDoes Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project) | Semaglutide Obesity / overweight | — | — | Active, not recruiting | 1 | May 2024 | 7 | |
| ASSETAcute Subcutaneous SemaglutidE in Acute Ischemic sTroke | Semaglutide Stroke | — | Ph 2 | Recruiting | 1 | Sep 2025 | — | |
| NCT05689372Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | Semaglutide Type 2 diabetes | — | — | By invitation | 1 | Nov 2026 | — | |
| STENO INTEN-CTScreening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes | Semaglutide Type 2 diabetes | — | Ph 4 | Recruiting | 1 | Jan 2029 | 1 | |
| Sema-RTxSemaglutide Treatment for Hyperglycaemia After Renal Transplantation | Semaglutide Diabetes (other / unspecified), Renal impairment, Type 2 diabetes | eGFR 10-40 | Ph 4 | Recruiting | 1 | Dec 2027 | — | |
| NCT05746039Feasibility of Semaglutide in Advanced Lung Disease | Semaglutide Obesity / overweight, Pulmonary Disease, Chronic Obstructive | BMI ≥30 | Ph 1/2 | Recruiting | 1 | Dec 2027 | — | |
| NCT05780905Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes | Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Recruiting | 1 | Mar 2026 | — | |
| HALLMARKThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | Semaglutide Chronic kidney disease | BMI 18.5-40 | Ph 2 | Recruiting | 1 | Oct 2027 | — | |
| NCT06050577The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | Semaglutide Osteoporosis / bone, Type 2 diabetes | — | Ph 2 | Active, not recruiting | 1 | Jan 2026 | — | |
| Sema-LitEffect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus | Semaglutide Diabetes (other / unspecified), Liver Transplant; Complications, Obesity / overweight | BMI ≥25 | Not applicable | Recruiting | 1 | Sep 2025 | 7 | |
| NCT06069622Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥30 | — | Recruiting | 1 | Oct 2026 | — | |
| NCT06132477Impact GLP-1 Agonists Following Bariatric | GLP-1 / incretin class catch-all, Semaglutide Bariatric Surgery, Obesity / overweight | BMI 30-80 | Ph 4 | Recruiting | 1 | Jul 2028 | 37 | |
| NCT06184568A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Mazdutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥28 | Ph 3 | Active, not recruiting | 1 | Sep 2025 | — | |
| DUTCH-WAISTDUTCH Weight Control in Atrial Fibrillation Study | Semaglutide Atrial fibrillation, Obesity / overweight | BMI ≥30 | Ph 4 | Recruiting | 1 | May 2026 | — | |
| NCT06234111Semaglutide and Physical Activity for Obesity and Multimorbidity | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥35 | — | Active, not recruiting | 1 | Oct 2026 | — | |
| NCT06269120SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary | Semaglutide Type 2 diabetes | HbA1c ≥7% | — | Recruiting | 1 | Mar 2026 | — | |
| NCT06271200Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET) | GLP-1 / incretin class catch-all, Semaglutide Metabolic syndrome, Obesity / overweight | BMI 27-45 | Not applicable | Recruiting | 1 | Oct 2027 | 24 | |
| NCT06363747The Medically Reproducing Bariatric Surgery (MRB) II Study | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2/3 | Active, not recruiting | 1 | Nov 2025 | 28 | |
| SEMA SMAAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | Semaglutide Type 1 diabetes | — | Ph 2/3 | Recruiting | 1 | Jan 2027 | — | |
| NCT06396416Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 | Semaglutide Chronic kidney disease, Obesity / overweight | — | Ph 4 | Recruiting | 1 | Feb 2026 | — | |
| NCT06410352Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome | Semaglutide Hypertension, Metabolic syndrome, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Recruiting | 1 | Sep 2025 | — | |
| NCT06411210Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment | Semaglutide Obesity / overweight, Type 1 diabetes | BMI ≥30 | Ph 2 | Recruiting | 1 | Apr 2028 | — | |
| FIT-HFEffect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | Semaglutide Heart failure, Obesity / overweight | BMI ≥30 | Ph 2/3 | Recruiting | 1 | Jun 2026 | — | |
| Pre-DMPrevention of Progression of Prediabetes, Obesity and CV Risk | Semaglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI 25-40 | Ph 1 | Recruiting | 1 | Jul 2027 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| NCT06461377The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | Semaglutide Diabetic neuropathy, Obesity / overweight, Type 2 diabetes | — | Ph 4 | Recruiting | 1 | Dec 2026 | 15 | |
| NCT06467604CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Mar 2027 | — | |
| NCT06487832Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness | GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Obesity / overweight | BMI 18.5-24.9 | Not applicable | Recruiting | 1 | Jul 2027 | — | |
| GLP-1 RAGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | Semaglutide Alcohol / substance use, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥35 | Not applicable | Not yet recruiting | 1 | Dec 2026 | — | |
| Sema-RMASemaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy | Semaglutide Chronic kidney disease, Type 2 diabetes | HbA1c ≥6.5% | Not applicable | Not yet recruiting | 1 | Mar 2025 | 1 | |
| SemaFatCardEffect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Semaglutide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Not yet recruiting | 1 | Sep 2024 | 22 | |
| PRESSUREPhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Semaglutide Bariatric Surgery, Bariatric Surgery Candidate, Obesity / overweight | — | Ph 1 | Recruiting | 1 | Sep 2027 | — | |
| NCT06581120GLP_1 RA Ultrasound Study | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk, Type 2 diabetes | BMI ≥35 | — | By invitation | 1 | Jul 2026 | — | |
| NCT06616961Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus | Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-29 | Ph 3 | Not yet recruiting | 1 | Feb 2025 | — | |
| NCT06649344A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | HRS9531, Semaglutide Type 2 diabetes | HbA1c ≤11% | Ph 3 | Active, not recruiting | 1 | Sep 2026 | — | |
| DECLARED-CTMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Prediabetes / glucose intolerance, Reproductive / infertility, Type 2 diabetes | BMI ≥27 | Not applicable | Recruiting | 1 | Aug 2026 | — | |
| NCT06716216A Study of BGM0504 in Participants with Type 2 Diabetes | BGM0504, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 3 | Recruiting | 1 | Mar 2026 | — | |
| STEP@STAHEvaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients | Semaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | — | Ph 4 | Active, not recruiting | 1 | Jul 2027 | — | |
| NCT06762314Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Semaglutide Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 2 | Recruiting | 1 | Sep 2027 | — | |
| METAfoieCharacterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 30-50 | Not applicable | Not yet recruiting | 1 | May 2026 | — | |
| Optimum 2A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | GZR18, Semaglutide Type 2 diabetes | — | Ph 3 | Active, not recruiting | 1 | Dec 2026 | — | |
| GALLOP2Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment | Semaglutide Stroke | — | Ph 3 | Not yet recruiting | 1 | Feb 2028 | — | |
| NCT06790160Study of Patients Being Treated With Anti-obesity Medication | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Recruiting | 1 | Dec 2027 | — | |
| NCT06801015Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Semaglutide, Tirzepatide Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥30 | Ph 4 | Active, not recruiting | 1 | Jan 2028 | — | |
| NCT06803888Bariatric Surgery vs. Semaglutide vs. Tirzepatide | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Active, not recruiting | 1 | Jul 2027 | — | |
| NETsImpact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps) | GLP-1 / incretin class catch-all, Semaglutide Chronic kidney disease, Diabetes (other / unspecified), Healthy volunteers | — | — | Recruiting | 1 | Dec 2030 | — | |
| NCT06827002Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults | Semaglutide Obesity / overweight | BMI 25-34 | Ph 1/2 | Active, not recruiting | 1 | Feb 2026 | 9 | |
| NCT06830343The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity | Semaglutide Obesity / overweight | BMI 24-28 | Ph 1 | Recruiting | 1 | Aug 2026 | — | |
| JOULE-MARSJOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity | Semaglutide Obesity / overweight | BMI ≥2 | Ph 4 | Recruiting | 1 | Dec 2027 | — | |
| TRIM-IRResponse to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI 30-40 | — | Recruiting | 1 | Aug 2026 | — | |
| NCT06863363PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults | Semaglutide Obesity / overweight | BMI ≥28 | Ph 4 | Not yet recruiting | 1 | — | — | |
| NCT06884293A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | Mazdutide, Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 3 | Active, not recruiting | 1 | Dec 2026 | — | |
| LEAN-PREPLEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Semaglutide, Tirzepatide Obesity / overweight | — | Not applicable | Recruiting | 1 | Aug 2029 | 7 | |
| NCT06896981Semaglutide in Women With Polycystic Ovary Syndrome and Obesity | Semaglutide Obesity / overweight, PCOS | Female | Ph 2/3 | Recruiting | 1 | Oct 2025 | — | |
| NCT06903923Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight | — | Ph 2 | Recruiting | 1 | Feb 2030 | — | |
| GAINPCCONTROLInvestigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Semaglutide Obesity / overweight, Oncology | Male | Ph 4 | Recruiting | 1 | Jul 2026 | — | |
| OBES1TYSemaglutide Treatment in Type 1 Diabetes | Semaglutide Obesity / overweight, Type 1 diabetes | BMI ≥30 | Ph 3 | Not yet recruiting | 1 | Jun 2028 | — | |
| NCT06924697Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients | GLP-1 / incretin class catch-all, Semaglutide Alcohol / substance use, Type 2 diabetes | Male | Not applicable | By invitation | 1 | Jan 2026 | 32 | |
| NCT06934655Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth | Semaglutide Bariatric Surgery, Obesity / overweight | — | Ph 3 | Not yet recruiting | 1 | Nov 2030 | — | |
| SEMPSOEffect of Semaglutide in Patients With Psoriasis and Obesity | Semaglutide Obesity / overweight, Psoriasis / psoriatic arthritis | — | Ph 3 | Recruiting | 1 | Jul 2026 | — | |
| SIGNALUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | Semaglutide Type 2 diabetes | — | Ph 4 | By invitation | 1 | Nov 2026 | — | |
| NCT06959784Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | Semaglutide Obesity / overweight, Type 2 diabetes | BMI 24-32.5 | Ph 4 | By invitation | 1 | Dec 2026 | — | |
| MODERNMitigation of Cardiovascular Disease Risks in Children With Extreme Obesity | Semaglutide Obesity / overweight | Age 12-17 | — | Recruiting | 1 | Jul 2026 | — | |
| NCT06975111Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Semaglutide Dyslipidemia, Hypertension, Obesity / overweight, Reproductive / infertility | Female | Ph 2/3 | Recruiting | 1 | Oct 2029 | 25 | |
| NCT06980623Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction | Semaglutide, Tirzepatide Heart failure, Type 2 diabetes | — | — | Active, not recruiting | 1 | Nov 2025 | — | |
| NCT06983171Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice | Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Sep 2028 | — | |
| ONSETImpact of Semaglutide on Tobacco Use and Related Health Behaviors | Semaglutide Alcohol / substance use, Obesity / overweight | BMI ≥30 | Ph 4 | Recruiting | 1 | May 2028 | — | |
| NCT06989177Probiotic Intervention on Body Weight | Semaglutide Healthy volunteers, Obesity / overweight | BMI ≤24 | Not applicable | Recruiting | 1 | Dec 2026 | — | |
| NCT06989203Protein Supplementation Intervention on Body Weight | Semaglutide Healthy volunteers, Obesity / overweight | BMI ≤24 | Not applicable | Recruiting | 1 | Dec 2026 | — | |
| RAMBOThe Role of the Amylin Analogue Cagrilintide in Bone Metabolism | CagriSema / cagrilintide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 1 | Recruiting | 1 | May 2028 | — | |
| GUARD-1Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | Semaglutide Chronic kidney disease, Type 2 diabetes | — | Ph 4 | Not yet recruiting | 1 | Jul 2027 | — | |
| PLASTICBrain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Semaglutide Obesity / overweight | — | Ph 3 | Not yet recruiting | 1 | Apr 2031 | — | |
| METSAFEMetabolic Surgery for Atrial Fibrillation Elimination | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Atrial fibrillation, Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Not yet recruiting | 1 | Dec 2029 | — | |
| STARSEfficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial | Semaglutide Stroke | — | Ph 3 | Not yet recruiting | 1 | Jul 2027 | 12 | |
| PasGrasPrevent and Reverse Obesity in Children, Adolescents and Young Adults | Semaglutide Obesity / overweight | BMI ≥25 | Not applicable | Not yet recruiting | 1 | Jan 2027 | 19 | |
| NCT07036172Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients | Semaglutide Obesity / overweight | BMI ≥28 | Ph 3 | Recruiting | 1 | Apr 2026 | — | |
| SEM-TIR24-h Energy Expenditure and Anti-obesity Medication | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | By invitation | 1 | Jun 2026 | — | |
| BETTER-GLP1Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Feeding And Eating Disorders, Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Nov 2027 | — | |
| NCT07057310Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Semaglutide, Tirzepatide Obesity / overweight, Reproductive / infertility | BMI ≥30 | Ph 4 | By invitation | 1 | Dec 2026 | — | |
| OPTIMALOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Hepatic impairment, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 1 | Feb 2029 | — | |
| NCT07073053The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms | Semaglutide Cardiovascular disease, Type 2 diabetes | — | Ph 4 | Not yet recruiting | 1 | Jul 2028 | — | |
| NCT07073417A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | Ecnoglutide (XW003), Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Active, not recruiting | 1 | Feb 2027 | — | |
| NCT07091500Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity | Semaglutide Obesity / overweight, Sarcopenia / muscle | BMI ≥30 | Not applicable | Recruiting | 1 | Aug 2028 | — | |
| NCT07092618Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation | Semaglutide Obesity / overweight | BMI ≥22 | Ph 2/3 | Recruiting | 1 | Aug 2025 | — | |
| REFORMComparison of Body Composition Changes With Weight Loss Interventions | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | BMI 35-60 | — | Recruiting | 1 | Sep 2026 | — | |
| SEMAMOODDoes Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity | Semaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥27 | Ph 4 | Recruiting | 1 | Sep 2027 | — | |
| NCT07139548A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | RAY1225, Semaglutide Type 2 diabetes | BMI ≥20 | Ph 3 | Not yet recruiting | 1 | Dec 2026 | — | |
| NCT07150975Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | GZR18, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥28 | Ph 3 | Recruiting | 1 | Jun 2027 | — | |
| OUTSTEP-1Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study. | Semaglutide Obesity / overweight | — | — | By invitation | 1 | Sep 2026 | — | |
| NCT07169136Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, PCOS | Female | — | Recruiting | 1 | Dec 2026 | 4 | |
| SILENCEDStudying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment | Semaglutide Obesity / overweight | BMI ≥25 | Ph 1/2 | Recruiting | 1 | Dec 2025 | — | |
| NCT07178145Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction | Semaglutide Heart failure | EF ≥50% | Ph 4 | Recruiting | 1 | Sep 2029 | 38 | |
| ADIPOLIVEVisceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | Semaglutide Chronic kidney disease, Type 2 diabetes | eGFR 60-89 | — | Recruiting | 1 | Dec 2027 | — | |
| NCT07187856Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus | PG-102 / RT-114, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 2 | Not yet recruiting | 1 | Sep 2026 | — | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| NCT07195994A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c 6-6.5% | Not applicable | Recruiting | 1 | Sep 2026 | — | |
| NCT07202247Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Apr 2028 | — | |
| NCT07207148People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | GLP-1 / incretin class catch-all, Semaglutide Multiple sclerosis, Obesity / overweight | BMI ≥24 | — | Recruiting | 1 | Apr 2028 | 14 | |
| PROBIO-GLP1Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Not yet recruiting | 1 | Apr 2027 | — | |
| OBOE-MayoIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | Semaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥30 | Ph 4 | Recruiting | 1 | Feb 2028 | — | |
| CRAVECessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder | Semaglutide Alcohol / substance use | — | Ph 3 | Not yet recruiting | 1 | Apr 2028 | — | |
| GL1DER HIV RCTGLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Semaglutide Alcohol / substance use, HIV | BMI ≥23 | Ph 2 | Recruiting | 1 | Oct 2029 | — | |
| TEXPEFTailored Exercise Training Study Among Adults With HFpEF | Semaglutide, Tirzepatide Heart failure, Obesity / overweight | BMI ≥28 | Ph 2/3 | Recruiting | 1 | Dec 2026 | — | |
| NCT07223983Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) | Semaglutide Alcohol / substance use, Bariatric Surgery, Obesity / overweight | BMI ≥30 | Ph 1 | Recruiting | 1 | Oct 2026 | 1 | |
| NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk | — | Ph 1 | Recruiting | 1 | Jun 2026 | — | |
| CASCADESAnti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes | Semaglutide Cardiovascular disease, Prediabetes / glucose intolerance | — | Ph 4 | Recruiting | 1 | Aug 2029 | 1 | |
| GLIMMERImpact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Dec 2027 | — | |
| WAITWaiting on Atrial Fibrillation Intervention Therapy (WAIT) Study | Semaglutide Atrial fibrillation, Obesity / overweight | BMI ≥30 | Ph 4 | Not yet recruiting | 1 | Dec 2028 | — | |
| NCT07276763Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention | Dulaglutide, Semaglutide Perioperative / gastric aspiration risk | — | — | Not yet recruiting | 1 | Dec 2025 | — | |
| NCT07280221WEgovy Real World Assessment of Weight Loss in Korea | Semaglutide Obesity / overweight | — | — | By invitation | 1 | Oct 2027 | — | |
| NCT07293325Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Apr 2027 | — | |
| RESTImpact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 1 | Sep 2028 | — | |
| GALACTUSEffect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Semaglutide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | EF ≥50% | Ph 3 | Recruiting | 1 | Aug 2026 | — | |
| EPIC-CTEpicardial Cardiac Fat-CT (EPIC-CT) | Semaglutide Cardiovascular disease | EF ≥50% | Ph 3 | Recruiting | 1 | Jan 2027 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| MAGvMEDSide-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 30-40 | Not applicable | Recruiting | 1 | Jun 2027 | — | |
| NCT07319975Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Semaglutide, Tirzepatide Obesity / overweight | BMI 30-40 | Not applicable | Not yet recruiting | 1 | Oct 2026 | — | |
| BetaBeta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | BMI 23-45 | Ph 4 | Active, not recruiting | 1 | Dec 2027 | 11 | |
| REINFORCEIncretin Microdosing for Cardiometabolic Health in People With HIV | Semaglutide HIV, Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | May 2028 | — | |
| BS-GLPBariatric Surgery Combined With GLP-1 Receptor Agonists Study | Semaglutide Bariatric Surgery, Obesity / overweight | BMI ≥35 | Ph 1/2 | Recruiting | 1 | Dec 2027 | — | |
| IMPACT-MACSIMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight | BMI ≥27 | Not applicable | Recruiting | 1 | May 2030 | 8 | |
| NCT07390110Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) | Semaglutide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT07391267Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. | Semaglutide Chronic kidney disease, MASH / NAFLD / liver fibrosis, Type 2 diabetes | HbA1c ≤10% | Not applicable | Not yet recruiting | 1 | Dec 2028 | — | |
| NCT07392151Reversal to Normoglycemia by Treating Prediabetes | Semaglutide Cardiovascular disease, Prediabetes / glucose intolerance | — | Ph 3 | Not yet recruiting | 1 | Oct 2029 | — | |
| SEMAPSOEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Semaglutide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥25 | Ph 4 | Recruiting | 1 | Feb 2027 | — | |
| INTERCEPTINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Active, not recruiting | 1 | May 2026 | — | |
| SEMAFOLLOWWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity | Semaglutide Obesity / overweight | — | — | Not yet recruiting | 1 | Mar 2027 | — | |
